BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to treat cancer. Get up to date with the BeiGene solid tumor pipeline and clinical trials.
A summary of the latest developments from 12 studies in the treatment of non-small cell lung cancer (NSCLC), gastric cancers and other solid tumors presented at ESMO 2022.
Oral presentation at ESMO 2022 describing the potential for combining a PD-1 inhibitor with a kinase inhibitor to treat unresectable hepatocellular carcinoma (HCC).
Poster presented at ESMO 2022 describing the potential for combining immunotherapy (a PD-1 inhibitor and a TIGIT inhibitor) as well as chemotherapy in patients with locally advanced, unresectable, or metastatic non-small cell lung cancer (NSCLC).